Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects Using Erythrocyte Mediated Angiography In Vivo

The goal of this clinical trial is to compare participants treated with latanoprost to those treated with Rocklatan (netarsudil/latanoprost) to determine whether the addition of netarsudil results in greater improvements in episcleral venous blood flow in adults with glaucoma or ocular hypertension. Episcleral venous blood flow will be measured using erythrocyte-mediated angiography (EMA) and laser speckle contrast imaging (LSCI).
The main questions this study aims to answer are:
* Does Rocklatan produce greater increases in episcleral venous blood flow than latanoprost alone?
* Can EMA and LSCI reliably detect changes in episcleral venous blood flow following treatment with these medications?
Participants will:
* Be randomized to receive either latanoprost or Rocklatan
* Undergo imaging of the episcleral veins using EMA and LSCI before, during, and after treatment, and
* Complete study visits that include standard ophthalmic examinations and intraocular pressure measurements.
Hypothesis: The investigators hypothesize that latanoprost, which primarily increases uveoscleral outflow, will not significantly affect the distal episcleral circulation. In contrast, Rocklatan, through its netarsudil component, is expected to produce measurable increases in episcleral venous flow.

Start Date02 Jul 2026

Sponsor / Collaborator

University of Maryland Baltimore

[+1]

NCT07425535

/ RecruitingEarly Phase 1IIT

Optic Nerve Head Strain in Non-glaucoma Subjects

Persons who do not have glaucoma will have pictures taken of the optic nerve with a standard camera before and 2 weeks after starting to take a daily glaucoma eye drop to lower eye pressure. These data will be used to compare to the same procedure performed with glaucoma patients to study how glaucoma injures the eye.

Start Date24 Jun 2026

Sponsor / Collaborator

The Johns Hopkins University

[+1]

100 Clinical Results associated with Latanoprost

100 Translational Medicine associated with Latanoprost

100 Patents (Medical) associated with Latanoprost

2,239

Literatures (Medical) associated with Latanoprost

01 Jan 2027·Value in Health Regional Issues

Cost-effectiveness of Stepwise Eye Drop Strategies for Open-Angle Glaucoma: A Markov Model Analysis From the Japanese Healthcare Perspective

Article

Author: Lai, Leanne ; Kashiwabara, Masami ; Nakagawa, Naoto ; Sakamoto, Yuka

OBJECTIVES:

Open-angle glaucoma is a common chronic condition that requires long-term eye drop treatments and thus economic burden. The study aims to evaluate the cost-effectiveness of stepwise eye drop treatments, focusing on latanoprost, timolol, and dorzolamide, from the Japanese healthcare payer's perspective.

METHODS:

The targeted eyedrops consisted of 3 individual active ingredients (latanoprost, timolol, and dorzolamide) and 2 fixed combinations (latanoprost/timolol and dorzolamide/timolol). In the absence of a predefined reference treatment strategy, all combination options were evaluated simultaneously. A Markov model simulated disease progression and treatment over a lifetime horizon. Transition probabilities were retrieved from some clinical trials. Costs were based on the 2024 Japanese Medical Fee Index and national drug price list. Health utilities were measured using European Quality of Life 5 Dimension 5 Level data from glaucoma patients. Deterministic and probabilistic sensitivity analyses addressed uncertainties, comparing brand-name and generic drug prices. Cost-effective threshold was set at 5 000 000 JPY/QALY (52 811 USD/QALY).

RESULTS:

Three cost-effective strategies were identified: timolol followed by dorzolamide/timolol, latanoprost followed by timolol, and timolol followed by latanoprost, with acceptability of 0.271, 0.256, and 0.193 at the threshold, respectively. Dorzolamide alone as a first-line therapy was not cost-effective. For generic drugs, starting with latanoprost followed by timolol, or vice versa, and using fixed combination strategies were cost-effective.

CONCLUSIONS:

For brand-name drugs, latanoprost followed by timolol or a timolol-first strategy with dorzolamide were the most cost-effective. For generics, starting with latanoprost or timolol, and following fixed combinations, were cost-effective. A timolol-first strategy followed by dorzolamide was cost-effective for brand-name drugs but not for generics.

01 Nov 2026·EXPERIMENTAL EYE RESEARCH

Intraocular pressure reduction attenuates form-deprivation myopia by modulating scleral extracellular matrix remodeling via the TGF-β1/Smad signaling pathway

Article

Author: Wang, Hao ; Ju, Hong

OBJECTIVE:

This study aimed to investigate whether intraocular pressure (IOP) reduction achieved separately using two mechanistically distinct IOP-lowering agents, brinzolamide and latanoprost, attenuates form-deprivation myopia (FDM) by regulating scleral extracellular matrix (ECM) dynamics and to elucidate the underlying involvement of the TGF-β1/Smad signaling pathway.

METHODS:

We established a murine model of unilateral FDM with the contralateral untreated eye serving as an intra-individual control and assessed key ocular parameters, including IOP, axial length (AL), and refractive error (RE). Scleral tissues were subjected to hematoxylin and eosin (H&E) staining and Western blot analysis. Primary human scleral fibroblasts (HSFs) were exposed to hypoxia to mimic myopic stress, and cell viability, proliferation, and apoptosis were evaluated using Cell Counting Kit-8 (CCK-8), 5-ethynyl-2'-deoxyuridine (EdU), flow cytometry, and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assays. Protein expression of ECM-related markers and key components of the TGF-β1/Smad pathway was analyzed by Western blot. The functional role of the TGF-β1/Smad axis was further examined using the selective inhibitor LY2109761.

RESULTS:

IOP reduction induced separately by brinzolamide and latanoprost (via distinct mechanisms of action) effectively attenuated IOP elevation, axial elongation, and myopic shift in FDM mice, accompanied by preserved scleral architecture and normalized expression of type I collagen, matrix metalloproteinase-2 (MMP2), tissue inhibitor of metalloproteinase-2 (TIMP-2), and α-smooth muscle actin (α-SMA). In HSFs under hypoxia, both IOP-lowering agents exerted consistent protective effects, restoring cell viability and proliferation, suppressed apoptosis, and reversed hypoxia-induced ECM dysregulation. These protective effects were associated with upregulation of TGF-β1, phosphorylated Smad2 (p-Smad2), and phosphorylated Smad3 (p-Smad3) in both in vivo and in vitro models. Co-treatment with LY2109761 completely abolished the beneficial effects of IOP reduction on ocular biometry, scleral structure, cellular function, and ECM protein expression.

CONCLUSION:

Intraocular pressure reduction achieved separately via two mechanistically distinct pharmacological approaches mitigates FDM by preserving scleral integrity through modulation of ECM remodeling, an effect mediated via activation of the TGF-β1/Smad signaling pathway.

01 Nov 2026·JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Changes in Corneal Epithelial Barrier Function and Zonula Occludens-1 Distribution with Concomitant Use of Silver Nitrate and Latanoprost in Rabbits

Article

Author: Sasaki, Makoto ; Ishida, Hidetoshi ; Sasaki, Yu ; Kiyoi, Takeshi ; Masuoka, Takayoshi ; Kubo, Eri ; Sasaki, Hiroshi ; Fukuda, Masamichi

Purpose::

This study investigated the effects of silver nitrate (AgNO 3 ), a preservative in ophthalmic solution, alone and in combination with latanoprost (LP), on corneal epithelial barrier function and zonula occludens-1 (ZO-1) distribution in the corneal epithelium of rabbits.

Methods::

Twelve adult male albino New Zealand white rabbits (weighing 3.0–3.5 kg) were the subjects in this study. These mature rabbits received five instillations at 5-min intervals of AgNO 3 (0.01, 0.1, or 1%), benzalkonium chloride (BAK 0.02%), LP (0.005%) alone, or LP combined with AgNO 3 (0.01 or 1%). Corneal resistance (CR) was measured, and histological analyses were performed.

Results::

AgNO 3 1% increased CR (108.2%); however, CR significantly decreased when combined with LP ( P < 0.05). Marked CR reduction was observed in the eyes administered BAK and LP + AgNO 3 1%. Immunostaining showed preserved ZO-1 in the eyes that received AgNO 3 1% and LP + AgNO 3 0.01%, whereas those that received BAK, LP alone, and LP + AgNO 3 1% demonstrated disrupted ZO-1.

Conclusions::

A high concentration of AgNO 3 with LP exacerbated corneal epithelial barrier impairment, which highlights the importance of preservative concentration control in ophthalmic formulations.

115

News (Medical) associated with Latanoprost

16 Sep 2026

·www.globenewswire.com

Data on Nicox's NCX 470 to be presented at AAOpt Annual Meeting 2026

Press Release Data on Nicox's NCX 470 to be presented at AAOpt Annual Meeting 2026September 16, 2026 – release at 7:30 amSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that key scientific data on NCX 470 will be presented at the upcoming American Academy of Optometry (AAOpt) Annual Meeting 2026 (September 30 – October 3, 2026, Anaheim, CA, U.S.). Nicox will also be participating in several key ophthalmology, financial and industry conferences in the second half of 2026.“NCX 470 is an investigational new drug for the reduction of intraocular pressure which has recently completed a multi-region Phase 3 clinical program. AAOpt provides an important opportunity to share the data from these trials directly with the optometrist community, which plays a central role in the diagnosis and ongoing management of glaucoma. This forum enables us to engage directly with optometrists and place the clinical findings for NCX 470 in the context of glaucoma management in everyday practice.” said Siobhan Garbutt, VP and Head of Clinical Development of Nicox.Data from Nicox’s clinical trials, Denali, Whistler and Mont Blanc has already been presented at a number of key ophthalmology conferences. All publications can be found on our website. AAOpt 2026 Annual Meeting – September 30 to October 3, 2026, Anaheim, CA, U.S. Presentation Details Title: The Denali Trial U.S. Subgroup: A Randomized Trial Comparing NCX 470 0.1% and Latanoprost 0.005% for Open-Angle Glaucoma or Ocular HypertensionType: Paper PresentationDate: Thursday, October 1, 2026 at 08:15 am (local time)Presenter: Nora Cothran, OD, Fellow of the American Academy of OptometryTitle: Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution (Nitric Oxide-Donating Bimatoprost): A Double-Masked, Placebo-Controlled, Phase 3b Clinical TrialType: Poster Presentation – Board #162Date: Thursday, October 1, 2026 at 4:30 pm (local time) Presenter: Siobhan Garbutt, PhDH2 Conference Attendance American Academy of Ophthalmology (AAO) – October 9-12, 2026 – New Orleans, Louisiana – United-StatesInvestor Access – October 6-7, 2026 – Paris, France Members of the Nicox team will be available for one-on-one meetings at these events. If you wish to set up a meeting, please contact us at communications@nicox.com. About NCX 470NCX 470 is a novel nitric oxide (NO)-donating bimatoprost eye drop that leverages the potent intraocular pressure (IOP)-lowering effects of NO and prostaglandin analogs (PGAs). NCX 470 incorporates Nicox’s proprietary NO-donating research platform and bimatoprost in a single molecule. NCX 470 is designed to release bimatoprost and NO into the eye to lower IOP by two different pathways in patients with open-angle glaucoma or ocular hypertension. NO is a well-known small, naturally occurring signalling molecule that plays a key role in the regulation of IOP through activation of soluble guanylate cyclase (sGC). NO brings additional IOP-lowering efficacy by enhancing aqueous humor drainage from the eye via a different mechanism of action to that of PGAs.NCX 470 has completed two Phase 3 clinical trials designed to fulfil the regulatory requirements for safety and efficacy to support NDA submissions in the U.S. and China, Mont Blanc and Denali. Both trials were positive and met the efficacy endpoints necessary for submission of a New Drug Application in the United States and China. NDAs for NCX 470 have been submitted in the U.S. and China. NCX 470 is an investigational product and has not yet been approved by the FDA.About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead late-stage development program is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa in the rest of the world. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX). For more information www.nicox.com Analyst coverageH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.com DisclaimerThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2024” and in section 4 of the “Rapport semestriel 2025” which are available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Attachment EN_AAOpt Annual Meeting NCX470 Data presentation_FINAL

Phase 3

05 Sep 2026

·www.prnewswire.com

Best Hair Growth Products for Men (2026): Happy Head Personalized Formulas Reviewed by Consumer365

NEW YORK, Sept. 5, 2026 /PRNewswire/ -- Consumer365 has reviewed Happy Head for its personalized approach to prescription hair-growth treatment, highlighting a selection of dermatologist-guided formulas designed for men managing thinning hair and male pattern hair loss. Best Hair Growth Products for Men Happy Head - a telehealth provider of personalized, dermatologist-prescribed hair-loss treatments Hair loss treatment has become increasingly personalized as prescription medicine moves into telehealth. Instead of relying on a single standardized formula, Happy Head connects customers with board-certified dermatologists who review medical history, allergies, hair-loss patterns and treatment goals before prescribing a personalized regimen. Treatments are then compounded and shipped directly to the customer. The approach is particularly relevant for consumers researching the best hair growth products for men, a category that includes topical treatments, oral medications and combination regimens. Happy Head offers each format through a telehealth model that does not require an in-person doctor visit. Happy Head offers personalized compounded formulas including dutasteride, finasteride, minoxidil to help you achieve your personal hair growth goals. Consumer365 Recognizes Happy Head's Personalized Treatment Model Consumer365 has recognized Happy Head for combining prescription hair-growth medicine with dermatologist oversight and personalized formulations. Happy Head states that all consultations are conducted by board-certified doctors. The platform also provides ongoing dermatologist support, allowing treatment formulas to be adjusted when medically appropriate. The company's formulations use FDA-approved active pharmaceutical ingredients, although compounded prescription formulations themselves are not FDA-approved. Happy Head's website identifies ingredients such as finasteride and minoxidil among its prescription options. The distinction is important for consumers evaluating prescription hair-loss care. The active ingredients may have established clinical uses, while compounded combinations require individualized medical oversight and are not equivalent to an FDA-approved finished drug product. Happy Head says most customers begin seeing progress within three to six months of consistent daily use. Early changes may include reduced shedding or the appearance of fine new hairs. Individual responses and timelines can vary. TopicalRx SuperSolutionTM ProBlend Topical Rx SuperSolution TM ProBlend is designed for consumers seeking a multi-ingredient topical prescription formula. The formulation includes up to 8% minoxidil alongside ingredients such as dutasteride, finasteride, cetirizine HCl, latanoprost, melatonin, caffeine, tretinoin, vitamin D3 and biotin. The formula is intended to address multiple aspects of hair and scalp health through a single topical treatment. Minoxidil is used to support hair growth, while dutasteride and finasteride target DHT, a hormone associated with male pattern hair loss. Tretinoin is included in the formulation to support minoxidil absorption. Happy Head describes its topical formulations as freshly compounded prescriptions rather than mass-produced products. Formula adjustments are available based on a customer's medical needs and dermatologist assessment. A higher concentration of an active ingredient does not automatically make a treatment appropriate for every person. Prescription-strength formulations require evaluation by a qualified healthcare provider. TopicalRx Solution + SuperCapsuleTM: Dutasteride & MinoxidilRx For men interested in combining topical and oral treatment, Happy Head offers Topical Rx Solution + SuperCapsule TM. The topical solution can contain 0.3% dutasteride, up to 8% minoxidil, retinoic acid and hydrocortisone. The accompanying SuperCapsule contains 0.5 mg dutasteride, 1.25 mg minoxidil and 2,000 IU of vitamin D3. The two-part regimen uses different delivery methods. The topical formula is applied directly to the scalp, for a total of 2.0ml daily, while the capsule provides oral medication once daily. Dutasteride and minoxidil are prescription medications that can carry risks and potential side effects, making medical screening an important part of the process. Happy Head's telehealth assessment is designed to determine whether a prescription treatment is appropriate. Medical history, allergies and the degree of hair loss are among the factors considered during the consultation. SuperCapsuleTM + ED Performance SuperCapsule TM + ED Performance takes a different approach by combining hair-loss treatment with medication for erectile dysfunction in a once-daily capsule. The formulation contains dutasteride, tadalafil and vitamin D3. Dutasteride is used in hair-loss treatment, while tadalafil is a prescription medication used for erectile dysfunction. Happy Head developed the combination for men seeking an oral hair-growth option alongside treatment for sexual performance concerns. The combination also underscores the importance of medical screening. Tadalafil can interact with certain medications and may not be appropriate for people with particular cardiovascular conditions. A dermatologist or other qualified healthcare professional can assess whether the treatment is suitable. The product provides an alternative to a topical routine for men who prefer oral medication. As with other prescription hair-growth treatments, outcomes can vary and consistent use is necessary for evaluating progress. What Sets the Happy Head Model Apart Happy Head's approach centers on prescription treatment supported by telehealth rather than a one-size-fits-all regimen. Customers complete an online assessment before connecting with a board-certified dermatologist. Once a prescription is approved, the treatment is prepared and shipped directly to the customer. Happy Head reports that more than 1 million prescriptions have been delivered through its platform. The company also says its treatments are shipped monthly in discreet packaging, with refills automatically sent as part of eligible subscriptions. Pricing varies according to the formulation and ingredients. Happy Head currently lists custom compounded prescription formulas ranging from $59 to $119 per month. Promotional savings and subscription terms can change over time. For consumers comparing the best hair growth products for men, the key consideration is not simply the number of ingredients or strength of a formula. Hair loss can have different causes, and prescription medications have different safety considerations. A dermatologist-guided assessment can help determine whether topical medication, oral treatment or a combination approach is appropriate. Consumer365's recognition of Happy Head highlights the growing role of personalized telehealth in hair-loss care. With multiple prescription formats and dermatologist oversight, the platform gives men a range of treatment pathways while keeping medical evaluation central to the process. The full review is available at the Consumer365 website. Happy Head offers personalized compounded prescription treatments. Compounded medications are not FDA-approved, and some ingredients or uses discussed may be prescribed off-label. Treatment suitability and results vary. A licensed healthcare provider must determine whether a treatment is appropriate. Review Happy Head's Drug Safety & Information. About Happy Head Happy Head is the industry-leading, dermatologist-founded telehealth company redefining the future of precision hair care. Founded in 2021 by renowned dermatologists and hair loss experts, Dr. Ben Behnam and Dr. Sean Behnam, the company combines clinical expertise with breakthrough science to deliver personalized solutions for hair preservation and restoration. From custom-compound topicals to its innovative StrandIQ™ DNA Starter Kit, Happy Head empowers individuals to make informed decisions to take control of their hair health journey from the privacy of their home, with recommendations that are clinically proven and tailored to individual needs. The mission is simple: help people regrow their hair and restore their confidence with personalized, medical-grade treatments that actually work. Learn more at . About Consumer365.org: Consumer365 provides consumer news and industry insights. As an affiliate, Consumer365 may earn commissions from sales generated using links provided. SOURCE Consumer365.org 21% more press release views with Request a Demo

Drug Approval

31 Aug 2026

·www.prnewswire.com

Kowa Pharmaceuticals America Announces FDA Acceptance of New Drug Application for K-911, an Investigational IOP-Lowering Eye Drop for Patients with Open-Angle Glaucoma or Ocular Hypertension

Investigational K-911 is a once-daily nitric oxide-donating bimatoprost eye drop designed to lower intraocular pressure NDA is supported by two pivotal Phase 3 trials FDA assigns PDUFA target action date of April 30, 2027 MONTGOMERY, Ala., Aug. 27, 2026 /PRNewswire/ -- Kowa Pharmaceuticals America, Inc. (KPA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for K-911 (bimatoprost grenod, also known as NCX 470), an investigational topical ophthalmic monotherapy for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2027. "The FDA's acceptance of the NDA for K-911 marks an important milestone as we work toward bringing a potential new treatment option to people living with open-angle glaucoma or ocular hypertension," said Joe Barna, CPA, Chief Executive Officer and President of KPA. "We're proud to bring Kowa's decades of global ophthalmology experience to the U.S. eye care community, and we look forward to working with the FDA throughout the review process." K-911 is an investigational, once-daily nitric oxide-donating bimatoprost monotherapy formulated as a sterile ophthalmic solution and engineered to lower IOP through two distinct aqueous humor outflow pathways. Nitric oxide is intended to enhance conventional outflow through the trabecular meshwork-Schlemm's canal pathway, while bimatoprost enhances uveoscleral outflow. The NDA is supported by two pivotal Phase 3 clinical trials, Mont Blanc and Denali, which evaluated K-911 0.1% against latanoprost 0.005%, a widely used prostaglandin analog, in patients with OAG or OHT. Despite the availability of multiple treatment options, achieving and maintaining appropriate IOP control remains an important treatment goal for patients with OAG or OHT, with individual needs varying from patient to patient and over time. In February 2024, Kowa Company, Ltd. and Nicox S.A. entered into an exclusive licensing agreement for the development, manufacturing and commercialization of K-911 in Japan, followed by an agreement in July 2025 granting Kowa rights to develop and commercialize K-911 in the United States and other licensed territories. Nicox, which discovered and developed K-911 and led the Mont Blanc and Denali Phase 3 trials, continues to provide development expertise and support, while Kowa is responsible for U.S. regulatory and commercialization activities. The FDA's acceptance of the K-911 NDA for filing marks the next regulatory milestone for K-911 in the U.S. as the application proceeds through FDA review. Following confirmation of a PDUFA target action date of April 30, 2027, Kowa anticipates a U.S. commercial launch in the second half of 2027, subject to approval. About Glaucoma and Ocular Hypertension Glaucoma is a progressive eye disease that can cause irreversible optic nerve damage leading to vision loss and potential blindness.1,2 More than 4.2 million adults in the U.S. live with glaucoma, with open-angle glaucoma representing the most common form of the disease.3 Lowering intraocular pressure is the only proven approach to slowing glaucoma disease progression.1,2 Ocular hypertension is characterized by elevated intraocular pressure without detectable optic nerve damage or vision loss.4 Although ocular hypertension may not cause symptoms, elevated IOP is an important risk factor for the development of glaucoma.4 An estimated 3-6 million people in the U.S. live with ocular hypertension.4 About K-911 K-911 (bimatoprost grenod), also known as NCX 470, is an investigational, once-daily nitric oxide-donating bimatoprost eye drop being developed for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The NDA is supported by the Phase 3 Mont Blanc and Denali trials. K-911 is an investigational product and has not yet been approved by the FDA. Kowa holds exclusive rights to develop and commercialize K-911 in the U.S. About Kowa Pharmaceuticals America, Inc. Kowa Pharmaceuticals America, Inc. (KPA) is a Montgomery, Alabama-based specialty pharmaceutical company with 18 years of experience developing and commercializing pharmaceuticals for the U.S. market. As part of Kowa Company, Ltd. (KCL), KPA is building on Kowa's decades of global ophthalmology expertise as it expands its presence in the U.S. eye care community. For more information, please visit . References Cleveland Clinic. (2024, November 12). Glaucoma: What it is, symptoms, causes, types & treatment. Cleveland Clinic. National Eye Institute. (2025, November 26). Glaucoma. U.S. Department of Health and Human Services. Seminara, L. (2025, February 1). Updated prevalence of glaucoma in the United States. EyeNet Magazine. American Academy of Ophthalmology. Cleveland Clinic. (2022, December 19). Ocular hypertension: Causes, symptoms & treatment. Cleveland Clinic. Christian Vaughn, [email protected] SOURCE Kowa Pharmaceuticals America, Inc. 21% more press release views with Request a Demo

Phase 3License out/inNDA

100 Deals associated with Latanoprost

External Link

KEGG	Wiki	ATC	Drug Bank
D00356	Latanoprost	S01EE01	DB00654

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Eye Diseases	Canada	Orimed Pharma, Inc.	01 Dec 2025
Glaucoma	Japan	Viatris, Inc.	12 Mar 1999
Glaucoma, Open-Angle	United States	Upjohn US 2 LLC	05 Jun 1996
Ocular Hypertension	United States	Upjohn US 2 LLC	05 Jun 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glaucoma, Angle-Closure	Phase 2	United States	Santen SAS	01 Nov 2010
Glaucoma-Related Pigment Dispersion Syndrome	Phase 2	United States	Santen SAS	01 Nov 2010
Corneal Diseases	Clinical	Taiwan Province	Santen Pharmaceutical Co., Ltd.	02 Apr 2018
Exfoliation Syndrome	Clinical	United States	Pfizer Inc.	01 Aug 2000
Dry Eye Syndromes	Preclinical	Germany	Novaliq GmbH	15 May 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04702789 (PRO-122, CTgov)	Phase 4	Glaucoma, Open-Angle	28	Dorzolamide-timolol-brimonidine+latanoprost (Arm 1; Dorzolamide-timolol-brimonidine and Latanoprost; Krytantek Ofteno PF® and Gaap Ofteno PF®)	hbpcwpuefw(uahhvreabt) = hacrpeuoyg fctgyoppgg (jkvngiazyo, 1.49) View more	-	07 May 2026
				DORZOLAMIDE HYDROCHLORIDE/TIMOLOL MALEATE+latanoprost (Arm 2; Dorzolamide-timolol and Latanoprost; Eliptic Ofteno PF® and Gaap Ofteno PF®)	hbpcwpuefw(uahhvreabt) = lndqvcygsr fctgyoppgg (jkvngiazyo, 2.48) View more
ARVO2026	Not Applicable	Glaucoma, Open-Angle	40	bimatoprost	fjtrtvtofk(zbqkoazopo) = vbsrifoacz ewdogmpjiv (eqfuzebgdq ) View more	Negative	03 May 2026
NCT04702789 (Pubmed \| Clin Ophthalmol)	Phase 4	Glaucoma	26	Timolol, Dorzolamide, Brimonidine, Latanoprost	xtflfaorim(atrlgxkxur) = neither presented drug-related AEs gjbhuibjxp (qhrzrwbwcc ) View more	Positive	01 Aug 2025
				Timolol, Dorzolamide, Latanoprost
NCT01677507 (ARVO2025)	Phase 1	Ocular Hypertension	106	Latanoprost	tejfkeiefh(ulqnashdql) = pdbsumpnke irvuzogrzf (qcxbhxqgok )	Positive	04 May 2025
				Timolol	tejfkeiefh(ulqnashdql) = ffgkscajzv irvuzogrzf (qcxbhxqgok )
NCT04060758 (NEWS)	Phase 2	Glaucoma	17	拉坦前列素眼部植入剂-PA5108	kaptejdide(ifxewxmzge) = Clinical results have reached the endpoint kmcrjscgnk (uaviqibezz )	Negative	30 Oct 2024
NCT04133311 (CTgov)	Phase 3	Glaucoma, Open-Angle	386	DE-130A (DE-130A)	nwbnbmmrxi(wdcnpmevoo) = nuofenxbtj uswlffdzkx (sgyrumjcze, 0.25) View more	-	28 May 2024
				Xalatan® (Xalatan®)	nwbnbmmrxi(wdcnpmevoo) = zfiwvgxlbs uswlffdzkx (sgyrumjcze, 0.26) View more
NCT04405245 (CTgov)	Phase 2	Glaucoma, Open-Angle	194	AKB-9778 4%+Latanoprost ophthalmic solution (AKB-9778 4% QD + Latanoprost)	hnkfkexnos(xfxxrbkbbe) = ybbrdyners taedeerepb (pwowhzyvwu, 0.258) View more	-	25 May 2023
				AKB-9778 4%+Latanoprost ophthalmic solution (AKB-9778 4% BID + Latanoprost)	hnkfkexnos(xfxxrbkbbe) = jikoaxavep taedeerepb (pwowhzyvwu, 0.257) View more
NCT05165290 (CLEAR, GlobeNewswire) Manual	Phase 3	Glaucoma	-	TC-002	uspmejggbz(aglvrkiaie) = achieved the primary efficacy endpoint, which is the difference in mean change from baseline in IOP at weeks two, six and twelve at 8:00 am, 10:00 am and 4:00 pm. ihcoituemz (wxpusovkgr ) Met	Positive	29 Sep 2022
				Latanoprost ophthalmic solution
NCT00934089 (CTgov)	Phase 2	Glaucoma, Open-Angle	31	Taprenepag+Latanoprost (Taprenepag+Latanoprost)	dhfmmsaqcb(pdtznzixok) = kphijcjgyc gxvxbdbldp (wglzbxkfqp, 3.264) View more	-	03 May 2021
				Taprenepag+Latanoprost (Taprenepag+Latanoprost Vehicle)	dhfmmsaqcb(pdtznzixok) = vuhowkijtm gxvxbdbldp (wglzbxkfqp, 2.786) View more
NCT02466399 (CTgov)	Phase 2	Glaucoma, Open-Angle	80	POLAT-001 (POLAT-001)	sfijiijrer(bgjdvejvzj) = aigyjlwjlw bamtrwqdjp (forecmnrdg, 4.6) View more	-	16 Nov 2020
				Latanoprost ophthalmic solution (Latanoprost Ophthalmic Solution)	sfijiijrer(bgjdvejvzj) = ykystsyhyh bamtrwqdjp (forecmnrdg, 2.9) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis